Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

5.3K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.3K
Cancer Vaccines01:30

Cancer Vaccines

1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Cancer Survival Analysis01:21

Cancer Survival Analysis

808
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
808
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The role of surgical margins as outcome metrics in a quality assurance program for robot-assisted radical prostatectomy.

International journal for quality in health care : journal of the International Society for Quality in Health Care·2026
Same author

Leveraging [<sup>18</sup>F]F-Piflufolastat PET for PBPK Prediction of Tissue Distribution and Therapy Optimization in Prostate Cancer.

Clinical and translational science·2026
Same author

Nodal maximum standardised uptake value improves PSMA-PET/CT-based nodal staging in intermediate- and high-risk prostate cancer.

BJU international·2026
Same author

A trophoblast glycoprotein specific 5T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignancies.

Clinical immunology (Orlando, Fla.)·2026
Same author

[<sup>177</sup>Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study.

The Lancet. Oncology·2026
Same author

Correction to: Addition of quantitative imaging parameters to visual analysis improves the accuracy of PSMA PET/CT for the local staging of primary prostate cancer.

European journal of nuclear medicine and molecular imaging·2026

相关实验视频

Updated: Mar 12, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

[前列腺癌] 这是什么?

André N Vis1,2, Esther H J Hamoen3, Jean-Paul A van Basten4

  • 1Amsterdam UMC, afd. Urologie, Amsterdam.

Nederlands tijdschrift voor geneeskunde
|March 11, 2026
PubMed
概括
此摘要是机器生成的。

前列腺癌通常通过PSA测试来诊断,可能不会影响预期寿命. 然而,侵略性形式和转移性疾病的死亡率很高,需要治疗可能会产生副作用.

更多相关视频

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

15.3K

相关实验视频

Last Updated: Mar 12, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

15.3K

科学领域:

  • 在瘤学瘤学.
  • 泌尿器科 泌尿器科 泌尿器科 泌尿器科

背景情况:

  • 前列腺癌是一个普遍的诊断,经常通过前列腺特异性抗原 (PSA) 检测来检测.
  • 这种疾病可以从无症状,不危及生命的疾病到具有显著死亡率的侵袭性形式.

研究的目的:

  • 提供前列腺癌诊断,治疗选择和相关结果的概述.
  • 突出管理局部化和转移性前列腺癌的挑战.

主要方法:

  • 审查已建立的诊断方法,包括PSA驱动的诊断.
  • 目前针对局部性前列腺癌的治愈治疗方法的总结.
  • 对转移性前列腺癌的治疗策略的概述.

主要成果:

  • 局部化前列腺癌治疗方法,如手术和放射治疗,具有治愈潜力,但可能引起副作用.
  • 荷尔蒙疗法是转移性疾病的首要治疗方法,通常用于组合或连续使用.
  • 转移性前列腺癌与高死亡率有关,尽管有治疗方法.

结论:

  • 有效管理前列腺癌需要平衡治疗效果与潜在的副作用.
  • 前列腺癌的晚期阶段,特别是转移性疾病,存在重大治疗挑战和不良预后.